Stock 600196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
23.19 CNY +1.35% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +3.02% -7.35%
Apr. 24 Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator MT
Apr. 18 China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 65,086 125,791 113,862 86,922 61,592 55,437 - -
Enterprise Value (EV) 1 77,050 139,217 127,150 100,183 80,958 71,129 73,204 70,345
P/E ratio 20.5 x 37.8 x 26.5 x 24.6 x 28.1 x 18.4 x 14.2 x 13.3 x
Yield 1.47% 0.8% 1.14% 1.19% 1.08% 1.8% 2.11% 2.61%
Capitalization / Revenue 2.28 x 4.15 x 2.92 x 1.98 x 1.49 x 1.23 x 1.09 x 1.03 x
EV / Revenue 2.7 x 4.59 x 3.26 x 2.28 x 1.96 x 1.58 x 1.44 x 1.3 x
EV / EBITDA 13.1 x 22.2 x 15.7 x 14.5 x 13.1 x 10.1 x 8.75 x 8.94 x
EV / FCF -109 x -75 x -137 x -64.1 x -42.3 x 15.3 x 47.6 x 42.3 x
FCF Yield -0.92% -1.33% -0.73% -1.56% -2.36% 6.53% 2.1% 2.36%
Price to Book 2.14 x 3.74 x 3.21 x 2.11 x 1.46 x 1.29 x 1.16 x 1.13 x
Nbr of stocks (in thousands) 2,562,899 2,562,899 2,562,899 2,672,157 2,672,399 2,672,399 - -
Reference price 2 26.60 53.99 48.94 35.24 25.03 23.19 23.19 23.19
Announcement Date 3/30/20 3/29/21 3/22/22 3/27/23 3/26/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 28,585 30,307 39,005 43,952 41,400 45,054 50,804 54,047
EBITDA 1 5,874 6,282 8,105 6,889 6,160 7,009 8,370 7,871
EBIT 1 4,494 4,721 6,314 4,657 3,308 3,603 4,654 4,711
Operating Margin 15.72% 15.58% 16.19% 10.59% 7.99% 8% 9.16% 8.72%
Earnings before Tax (EBT) 1 4,526 4,678 6,054 4,574 3,265 4,699 5,690 6,365
Net income 1 3,322 3,663 4,735 3,731 2,386 3,342 4,279 4,605
Net margin 11.62% 12.09% 12.14% 8.49% 5.76% 7.42% 8.42% 8.52%
EPS 2 1.300 1.430 1.850 1.430 0.8900 1.263 1.629 1.740
Free Cash Flow 1 -705.7 -1,857 -926.7 -1,564 -1,913 4,645 1,537 1,662
FCF margin -2.47% -6.13% -2.38% -3.56% -4.62% 10.31% 3.03% 3.08%
FCF Conversion (EBITDA) - - - - - 66.27% 18.37% 21.11%
FCF Conversion (Net income) - - - - - 139% 35.92% 36.09%
Dividend per Share 2 0.3900 0.4300 0.5600 0.4200 0.2700 0.4183 0.4897 0.6059
Announcement Date 3/30/20 3/29/21 3/22/22 3/27/23 3/26/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 10,096 11,957 10,382 10,893 10,270 12,341 10,871 10,445 9,305 10,699 10,691 10,814 10,631 11,295
EBITDA - - - - - - - - - - - - - -
EBIT 1 1,371 1,615 863.1 1,136 1,046 1,064 1,427 1,255 659.6 -34.69 654.6 518 874.5 677.4
Operating Margin 13.58% 13.5% 8.31% 10.43% 10.18% 8.62% 13.13% 12.02% 7.09% -0.32% 6.12% 4.79% 8.23% 6%
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - -
EPS 2 0.4200 0.4600 0.1800 0.4200 0.3500 0.4800 0.3700 0.3000 0.1900 0.0400 0.2700 0.3100 0.4600 0.4300
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 10/26/21 3/22/22 4/26/22 8/29/22 10/30/22 3/27/23 4/28/23 8/29/23 10/30/23 3/26/24 - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 11,964 13,426 13,289 13,261 19,366 15,692 17,767 14,908
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.037 x 2.137 x 1.639 x 1.925 x 3.144 x 2.239 x 2.123 x 1.894 x
Free Cash Flow 1 -706 -1,857 -927 -1,564 -1,913 4,645 1,537 1,662
ROE (net income / shareholders' equity) 11.6% 10.8% 12.4% 9.04% 5.29% 6.76% 8.25% 8.78%
ROA (Net income/ Total Assets) 4.53% 4.58% 5.35% 3.73% 2.18% 2.53% 2.9% 3.3%
Assets 1 73,341 79,904 88,433 100,022 109,663 132,086 147,745 139,511
Book Value Per Share 2 12.40 14.40 15.30 16.70 17.10 18.00 20.00 20.50
Cash Flow per Share 2 1.260 1.010 1.540 1.580 1.280 2.270 1.760 2.000
Capex 1 3,928 4,437 4,875 5,782 5,328 4,900 3,919 4,577
Capex / Sales 13.74% 14.64% 12.5% 13.15% 12.87% 10.88% 7.71% 8.47%
Announcement Date 3/30/20 3/29/21 3/22/22 3/27/23 3/26/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
23.19 CNY
Average target price
29.75 CNY
Spread / Average Target
+28.28%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Stock Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
-7.35% 7.65B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. Financials Shanghai Fosun Pharmaceutical (Group) Co., Ltd.